Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 21, 2023 16:30 ET | Source: Vaxart, Inc.

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet...
June 07, 2023 09:16 ET | Source: Vaxart, Inc.

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock,...
June 06, 2023 16:01 ET | Source: Vaxart, Inc.

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition,...
June 06, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate

No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2 norovirus vaccine studies over the next 3 months SOUTH SAN FRANCISCO, Calif., June ...
May 31, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET

SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to...
May 04, 2023 16:01 ET | Source: Vaxart, Inc.

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results

On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH...
April 28, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
March 29, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings,...
March 17, 2023 08:00 ET | Source: Vaxart, Inc.

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) --...
March 15, 2023 16:01 ET | Source: Vaxart, Inc.

Vaxart Provides Business Update and Full Year 2022 Financial Results

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance...